Survodutide in overweight or obesity with presumed or confirmed NASH

Phase 3, randomised, double-blind trial in obesity, Overweight and metabolic dysfunction-associated steatohepatitis (MASH) comparing Survodutide with Placebo (2 arms). Primary endpoints: Relative reduction in liver fat content of at least 30% from baseline to Week 48 and Relative change in body weight from baseline to Week 48. Planned start Jun 2024; status: authorised.